# Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects

> **NCT03123094** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Spesolimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03123094
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-16
- **Primary completion:** 2018-01-04
- **Final completion:** 2018-01-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123094, "Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03123094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*